Nonsteroidal Anti-Inflammatory Drug-Induced Hepatic Disorders

Manoukian, Aram V.; Carson, Jeffrey L.

doi:10.2165/00002018-199615010-00005

Cited by 53 publications

(11 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The lesions seen in histological studies are similar to those related to acetaminophen and centrilobular necrosis in severe cases (33). The female gender, being aged over 50 years, and the presence of immune disorders have all been reported as important risk factors in various studies (34). Further, a cohort study found that the risk of liver injury is increased tenfold in patients with rheumatoid arthritis when compared to patients with osteoarthritis (29).…”

Section: Contextmentioning

confidence: 99%

The Role of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the Treatment of Patients With Hepatic Disease: A Review Article

et al. 2016

View full text Add to dashboard Cite

ContextPatients with hepatic dysfunction suffer from many problems and associated complications in organs other than the liver. Therefore, it is very important to investigate the effects of different drugs in the treatment of these patients. Due to the high consumption of non-steroidal anti-inflammatory drugs (NSAIDs), studying the effects of these drugs in patients with hepatic dysfunction is particularly important.Evidence AcquisitionResearch studies published from 1958 to 2014 were investigated in the present study. The literature search was conducted based on the following keywords: non-steroidal anti-inflammatory drugs (NSAIDs), liver dysfunction, cirrhosis, pharmaceutical complications, drug-induced liver injury (DILI), and similar words from reliable resources. In total, 63 articles and two books (out of 179 initially identified resources) were included in the study.ResultsIn addition to significant hemostatic disorders and cardiovascular disorders, disorders of the renal, respiratory, and gastrointestinal systems, as well as disorders of the central nervous system, occur in patients with hepatic dysfunction. The various NSAIDs have different effects on different bodily systems. Therefore, the appropriate drug should be chosen based on both the condition of the disease and the severity of the dysfunction.ConclusionsDue to the potential adverse effects of NSAIDs in patients with hepatic disease, their impact on all bodily systems should be emphasized when determining whether their use is necessary. Further, the appropriate medication should be selected after a careful assessment of the severity of the disease and any associated complications. It is logical that medicines should only be prescribed by a qualified physician.

show abstract

Section: Contextmentioning

confidence: 99%

The Role of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the Treatment of Patients With Hepatic Disease: A Review Article

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The incidence of liver disease is very low and is relatively unimportant compared with the risk of peptic ulcer disease and gastrointestinal bleeding. Reports of hepatic injury range from insignificant and transient liver enzyme elevation to severe and fulminant hepatitis (Manoukian and Carson 1996). Long-term exposure to the anti-inflammatory agent such as phenylbutazone induces kidney tumors in rats and liver tumors in mice (Kari et al 1995).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the brain, renal, and hepatic effects of flunixin meglumine, ketoprofen, and phenylbutazone administration in Iranian fat-tailed sheep

Mozaffari

Derakhshanfar

2011

Trop Anim Health Prod

View full text Add to dashboard Cite

show abstract

“…Other study end points, such as liver injury, acute renal failure, blood dyscrasia, skin disorders, and anaphylaxis were rare, in agreement with results of other studies. [14][15][16][17][18][19] It is reassuring that no other major adverse events were identified except three cases of liver injury.…”

Section: Discussionmentioning

confidence: 99%

Low‐Dose Diclofenac, Naproxen, and Ibuprofen Cohort Study

et al. 1999

View full text Add to dashboard Cite

The risk of a newly diagnosed episode of upper gastrointestinal bleeding, acute liver and renal failure, agranulocytosis, aplastic anemia, severe skin disorders, and anaphylaxis was examined within 30 days after the first prescription for a low dose of diclofenac, naproxen, or ibuprofen in a cohort in the United Kingdom. We identified 22,146 persons using diclofenac (< or = 75 mg), 46,919 using naproxen (< or = 750 mg), and 54,830 using ibuprofen (< or = 1200 mg). Age, gender, and comorbidity were similar in the three cohorts. Overall 64 potential cases were identified, and 20 were confirmed by medical record review. Incidence rates (95% CI) of upper gastrointestinal bleeding/10,000 people using diclofenac, naproxen, and ibuprofen were 1.8 (0.5-4.6), 2.3 (1.2-4.2), and 0.4 (0.04-1.3), respectively. There were three cases of hepatic injury, one with naproxen and two with ibuprofen. Although low, the incidence of gastrointestinal toxicity remains the main serious adverse event for all study drugs.

show abstract

Nonsteroidal Anti-Inflammatory Drug-Induced Hepatic Disorders

Cited by 53 publications

References 41 publications

The Role of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the Treatment of Patients With Hepatic Disease: A Review Article

The Role of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the Treatment of Patients With Hepatic Disease: A Review Article

Evaluation of the brain, renal, and hepatic effects of flunixin meglumine, ketoprofen, and phenylbutazone administration in Iranian fat-tailed sheep

Low‐Dose Diclofenac, Naproxen, and Ibuprofen Cohort Study

Contact Info

Product

Resources

About